Local-First AI: Keep Your Data on Your Own Machine

Regulatory data is data that must not leak

The most valuable asset of an early-stage medtech, biotech, or medical device company is often not its code but its documentation. The intended use statement, the risk management file, the draft clinical evaluation reports, the verification protocols, the pilot data involving patients. Some of these may be considered personal, and even special category, data under KVKK and GDPR. Some are intellectual property that has not yet been patented or published.

What happens when you routinely paste this content into an AI tool? In a standard cloud-based assistant, your data goes to the vendor's server, is processed there, and is sometimes logged. Even if the terms of use exclude your data from model training, the data has physically left your control. For a startup, this creates two separate problems at the same time. The first is a compliance problem: you have added a third party that is hard to audit to your data processing chain. The second is a trust problem: when a hospital partner or an investor asks you "where does this regulatory file sit," the conversation goes very differently when your answer is "on our own machine."

The local-first approach cuts both of these problems at the source. AI tools run on your machine while processing your data, and the files that are produced stay on your own disk. For the model call, you use your own API key, that is, you send the request to the model directly, with no intermediary layer holding your data on your behalf in between.

Why bring-your-own-key makes a difference for compliance

Bring-your-own-key, that is, bring your own key, may look like a technical detail, but it is decisive from a data governance perspective. When you use your own key, the relationship with the model provider is directly between you and that provider. The software in between only formats the request and processes the result on your machine; it does not accumulate your data on its own server.

The concrete benefits can be listed as follows:

• A shorter data processing chain: From a KVKK and GDPR standpoint, the fewer the parties processing your data, the lower the compliance burden. When there is no intermediary SaaS layer, an additional data processor contract and an additional audit surface disappear.
• A direct contract with the model provider: Most enterprise model APIs offer commitments such as not using data for training and limited retention. You are subject to these commitments directly, rather than to an intermediary's terms.
• Auditability: You see where the data goes at a single point, in your own key usage. You do not have to separately investigate the logging and retention policy of an external service.

This architecture is one of the cleanest ways to manage the risk of data leakage. We previously addressed the importance of controlling which data goes where when preparing clinical data for AI in the article preparing clinical data for machine learning; local-first is the counterpart of the same discipline at the infrastructure layer.

Role-based AI team: it reports, it recommends, it does not decide

Local-first architecture is not an end in itself but the carrier of a well-structured AI team. The approach we design for early-stage regulated startups is not general-purpose autonomous agents. It is a team working on a role basis: one follows the regulatory and quality side (within the framework of MDR, FDA, TITCK, ISO 13485, IEC 62304), one compiles the literature and research, one produces business intelligence and content.

The critical principle is this: these workers report and recommend, but none of them sends, files, publishes, or approves anything on its own. At every step, the human operator, that is, the founder, is at the gate. They are not autonomous decision makers; accountability stays with the founder. In the context of a regulatory submission, this distinction is not accidental. In the classification of clinical decision support and similar software, the difference between software that merely informs the user's decision and software that decides in their place may be decisive for EU MDR and its counterpart in Turkey, the UTS/TITCK regulations. For this reason, the "recommends but does not execute" design is both an operational safety measure and a choice aligned with regulatory logic. (The exact classification is assessed separately for each product according to its intended use and to Rule 11 and the MDCG guidances; the statements here are a design rationale, not a compliance assurance.)

The general-purpose AI agent market is crowded. Our difference is not the agents themselves but the medtech-native perspective behind them. The regulatory depth and the real field credibility of a biomedical engineer who has shipped a clinical AI product make the output actually useful. We previously detailed the documentation nuances in the TITCK and CDSS context in the article how to prepare a TITCK CDSS clinical validation report.

Your first team before you can build your own

The positioning of this approach is clear: think of it as your first team, before you even reach the budget to hire your own team. A regulated startup moving forward with a single founder or a very small core team cannot put a regulatory expert, a research assistant, and a content team on payroll all at once. The role-based AI team fills this gap while preserving the founder's control and accountability.

An important distinction: this is not a self-service SaaS. It is delivered through Serteser Consulting, together with setup and expertise. That is, setting up the local-first infrastructure correctly, securely connecting your own key, and adapting the roles of the workers to your product and your regulatory roadmap are our job. In the end, you have a team whose data stays on your own machine, whose recommendations are put into effect with your approval, and whose regulatory depth comes from real field experience.

If you would like to discuss how to set up this approach for your regulated startup, you can review our professional consulting and clinical evidence services.